

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 7, 2024**

---

**INHIBIKASE THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39676**  
(Commission  
File Number)

**26-3407249**  
(IRS Employer  
Identification No.)

**3350 Riverwood Parkway SE, Suite 1900  
Atlanta, Georgia**  
(Address of Principal Executive Offices)

**30339**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (678) 392-3419**

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	IKT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The 2024 Annual Meeting of Stockholders (the “**Annual Meeting**”) of Inhibikase Therapeutics, Inc. (the “**Company**”) was held on June 7, 2024. The following proposals were approved at the Annual Meeting by the votes indicated:

Proposal One: To elect one director to the board of directors of the Company to serve as a Class I director, to serve until the Company’s 2027 annual meeting of stockholders, or until his successor is duly elected and qualified. The nominee for election was Milton H. Werner, Ph.D.

The following nominee was elected by the votes indicated to serve as a Class I director, to serve until the Company’s 2027 annual meeting of stockholders, or until his successor is duly elected and qualified:

<u>Name</u>	<u>Total Votes for Director</u>	<u>Total Votes Withheld from Director</u>	<u>Total Broker Non-Votes</u>
Milton H. Werner, Ph.D.	2,993,996	100,914	1,280,045

Proposal Two: To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

	<u>Total Votes</u>
For	4,352,312
Against	21,268
Abstain	1,375
Broker Non-Votes	0

Proposal Three: To approve an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 2,500,000 shares to replenish the number of authorized shares of common stock available for future grants.

	<u>Total Votes</u>
For	2,706,691
Against	377,250
Abstain	11,569
Broker Non-Votes	1,279,445

The following proposal was not adopted at the Annual Meeting by the votes indicated because the requisite approval percentage was not met:

Proposal Four: To approve an amendment to Article XII of the Company’s Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement to amend Section 1 of Article IV thereof.

	<u>Total Votes</u>
For	2,929,207
Against	120,362
Abstain	45,941
Broker Non-Votes	1,279,445

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 10, 2024

INHIBIKASE THERAPEUTICS, INC.

By: /S/ MILTON H. WERNER

Milton H. Werner, Ph.D.

President and Chief Executive Officer